Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory ...

Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

Investigators in this retrospective cohort study sought to determine long-term outcomes for patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to PARP inhibitors.

Ōtākou Whakaihu Waka researchers have been part of two studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis. Co-author on both studies, Dr.

Drug has different mechanism of action than existing injectables ...

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...

The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...

A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is associated with a lower risk for dementia in older adults with mood ...